Skip to main content
Roundtable/Forum

Forum on Drug Discovery, Development, and Translation

The Forum on Drug Discovery, Development, and Translation provides a neutral platform for dialogue and collaboration among thought leaders in government, industry, academia, consortia, foundations, journals, and patient groups. It serves as a hub and a catalyst for new ideas and partnerships, helping participants explore innovative solutions, find common ground, and turn ideas into meaningful action on biopharmaceutical innovation nationally and globally.

In progress

The National Cancer Policy Forum convened a workshop to explore how person-centered principles can be embedded in all stages of research, including design, activation, enrollment, data collection, completion, and outcome reporting to improve the relevance, quality, and impact of clinical cancer rese...

View details

Publications

Perspectives

It's Time to Harmonize Clinical Trial Site Standards

Perspectives

Real-World Evidence to Guide the Approval and Use of New Treatments

Perspectives

Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise

Perspectives

FDA and the Media: Lessons from Tysabri about Communication Uncertainty

Perspectives

Canadian Strategy on Patient-Oriented Research

Perspectives

Health Research as a Public Good

Perspectives

Novel Ways to Get Good Trial Data - The UK Experience

Perspectives

Developing a Clinical Trials Infrastructure in the United States

Perspectives

Transforming the Economics of Clinical Trials

Perspectives

Developing a Robust Clinical Trials Workforce

Perspectives

The Clinical Trials Enterprise in the United States - A Call for Disruptive Innovation

Perspectives

Aligning Cultural and Financial Incentives for Clinical Trials

Perspectives

Educating the Workforce for a Transformed Clinical Research Enterprise

Perspectives

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.